Yk 4 279

ChemScene Provide YK4279(CAS )Instock or Backordered impurities,Bulk custom synthesis,Formular C17H13Cl2NO4,MW 3662 bulk manufacturing, sourcing and procurement.

Yk 4 279. The small molecule inhibitor YK4279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J Jr, Kaidi A, Malik K Cancer Lett 17 Sep 10;. YK4279 Effectively Antagonizes EWSFLI1 Induced Leukemia in a Transgenic Mouse Model (Minas et al, Oncotarget 15) A Small Molecule Inhibitor of ETV1, YK4279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model (Rahim et al, PLoS One 14). Furthermore, combinations of YK4279 with vincristine, paclitaxel or the Aurora kinase A inhibitor MLN37/Alisertib show strong synergy, particularly at low doses Thus, YK4279 could potentially be used as a singleagent or in combination therapies for the treatment of highrisk and relapsing neuroblastoma, as well as other cancers.

YK4279 blocks specific protein interactions with EWSFLI1 including DDX5 and RHA leading to altered mRNA splicing as well as transcription 30, 31 YK4 279 can also block growth of other ETS driven cancers YK4 279 inhibited ERG and ETV1 derived malignant phenotypes in prostate cancer cells both. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 YK4279 inhibits Ewing's sarcoma family tumor (ESFT) cell growth, YK4279 induces apoptosis Characteristics Target DNA/RNA Synthesis inhibitor Receptor RNA helicase A Purification. We identified a small molecule, YK4279, that directly binds to EWSFLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models Herein, we tested in vivo.

YK4279 YK 4279 4,7dichloro3hydroxy32(4methoxyphenyl)2oxoethyl1Hindol2one 4,7dichloro3hydroxy3(2(4methoxyphenyl)2oxoethyl. Data Sheet SDS Handling Instructions YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 For research use only We do not sell to patients. Methods and FindingsWe recently reported the development of YK4279, a small molecule inhibitor of EWSFLI1 oncoprotein in Ewing’s Sarcoma Since ERG and ETV1 belong to the same class of ETS factors as FLI1, we tested the ability of YK4279 to inhibit biological functions of ERG and ETV1 proteins in prostate cancer.

Description YK4279 is a ETV1 inhibitor, which inhibitor proteinprotein interactions between ESFLI1 and RHAYK4279 effectively antagonizes EWSFLI1 induced leukemia in a transgenic mouse model YK4279 demonstrates specificity in targeting the oncogene EWSFLI1. The other, YK4279, is an experimental drug that targets an abnormality, called a fusion protein, that is commonly found in Ewing sarcoma tumors The researchers’ findings, published October 3 in Science Signaling, showed that, when combined, the two drugs work together to kill more cancer cells than either treatment alone. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is important for its oncogenic function.

Infiltrations We identified a small molecule, YK4279, that directly binds to EWSFLI1 and inhibits its oncogenic activity in Ewing sarcoma cell lines and xenograft mouse models Herein, we tested in vivo therapeutic efficacy and potential side effects of YK4279 in the transgenic mouse model with EWSFLI1. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is important for its oncogenic function.

YK4279 Catalog No T2275 CAS Purity 99% Datasheet MSDS YK 4279, an inhibitor of RNA Helicase A (RHA), binds to the oncogenic transciption factor EWSFLI1. Print YK 4279, Tocris Bioscience™ Click to view available options Quantity 10mg 50mg This item is not returnable View return policy CAS Molecular Formula C17H13Cl2NO4 Molecular Weight (g/mol) InChI Key. Find Ambeed, IncAMBH2D6FDD40 MSDS, related peerreviewed papers, technical documents, similar products & more at SigmaAldrich.

YK 4279, Tocris Bioscience™ Structure Search;. A new study from Boston University School of Medicine (BUSM) has discovered that a drug (YK4279) that was previously created to target one specific type of protein has much broader use against a. Print YK 4279, Tocris Bioscience™ Click to view available options Quantity 10mg 50mg This item is not returnable View return policy CAS Molecular Formula C17H13Cl2NO4 Molecular Weight (g/mol) InChI Key.

YK4279 is also found to potently inhibit biological activity of ERG (Kd value 117 µM) and ETV1 (Kd value 174 µM) resulting in suppression of both primary tumor growth and metastasis of fusion positive prostate cancer xenografts. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is important for its oncogenic function. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A (RHA) is important for its oncogenic function.

Reviews for YK 4279 There are currently no reviews for this product Be the first to review YK 4279 and earn rewards!. Discovered by Erkizan and colleagues (32), YK4279 was developed through combinatorial optimization of the aromatic ring of NSC, a small molecule capable of blocking interaction between RHA and EWS–FLI1 peptides (KD of 948 μmol/L by surface plasmon resonance). Methods and FindingsWe recently reported the development of YK4279, a small molecule inhibitor of EWSFLI1 oncoprotein in Ewing’s Sarcoma Since ERG and ETV1 belong to the same class of ETS factors as FLI1, we tested the ability of YK4279 to inhibit biological functions of ERG and ETV1 proteins in prostate cancer.

Find Ambeed, IncAMBH2D6FDD40 MSDS, related peerreviewed papers, technical documents, similar products & more at SigmaAldrich. YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1. YK4279 is also found to potently inhibit biological activity of ERG (Kd value 117 µM) and ETV1 (Kd value 174 µM) resulting in suppression of both primary tumor growth and metastasis of fusion positive prostate cancer xenografts.

YK 4279 is a small molecule inhibitor of ETV1 that plays an important role in the progression of prostate cancer The aim of this study was to evaluate the hypothesis that the combination of docetaxel and YK 4279 will have a synergistic effect on inhibiting growth and accelerating apoptosis in human prostate cancer cells. Reviews for YK 4279 There are currently no reviews for this product Be the first to review YK 4279 and earn rewards!. YK4279induced cell apoptosis of NB cells by Western blot assay SHSY5Y cells were treated with YK4279 (0, 01 μM, 03 μM, 1 μM, 3 μM) for 24 h Whole cell lysates were subjected to SDSPAGE and immunoblotted with antibodies against PARP and Caspase 3 to detect apoptosis βactin was detected as loading control.

TK‐216, clinical derivative of YK‐4‐279, is the first‐in‐class inhibitor of the Ets family of transcription factors Here, we characterized TK‐216 and YK‐4‐279 for their anti‐lymphoma activity and mechanism of action in lymphomas. YK4279 and enzastaurin are synergistic in inhibiting Ewing sarcoma cell lines A, the YK4279–resistant clone (TC71#3) displayed crossresistance to enzastaurin Sensitive versus resistant Ewing sarcoma cells were treated with enzastaurin and cell survival was measured using the WST1 cell proliferation assay. YK 4279 is also offered as part of the Tocriscreen Max Find out more about compound libraries available from Tocris.

YK4279 YK 4279 4,7dichloro3hydroxy32(4methoxyphenyl)2oxoethyl1Hindol2one 4,7dichloro3hydroxy3(2(4methoxyphenyl)2oxoethyl. YK 4279, Tocris Bioscience™ Structure Search;. YK4279 and TK216 demonstrated an antitumor activity across several lymphoma cell lines, which we validated in vivo We observed synergistic activity when YK4279 and TK216 were combined with the BCL2 inhibitor venetoclax and with the immunomodulatory drug lenalidomide.

YK4279 is a potent inhibitor of EWSFLI1 binding to RNA helicase A (RHA)YK4279 eliminates cyclin D levels by blocking the interaction of EWSFLI1 with RHA in EWSFLI1containing TC32 cells Please be kindly noted products are not for therapeutic use We do not sell to patients. YK4279 reduced the motility of LNCaP cells in a scratch assay and the invasive phenotype of both LNCaP and VCaP cells in a HUVEC invasion assay Fusionnegative PC3 cells were unresponsive to YK4279 SiRNA mediated ERG knockdown in VCaP cells resulted in a loss of drug responsiveness. YK4279 is an Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 At 10 µM, YK4279 blocks RHA binding to ESFLI1 and induces apoptosis of a panel of Ewing’s sarcoma tumor cell lines with IC₅₀ values ranging from 05.

YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 YK4279 inhibits Ewing's sarcoma family tumor (ESFT) cell growth, YK4279 induces apoptosis Characteristics Target DNA/RNA Synthesis inhibitor Receptor RNA helicase A Purification. Compound YK4279 Drug Target RNA helicase A Drug Target pathway Other. The small molecule inhibitor YK4279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis MadhuKollareddya AliceSherrardb Ji HyunParka MariannaSzemes a KelliGallachera ZsomborMelegha SebastianOlteanc Martin Michaelisd JindrichCinatlJre AbderrahmaneKaidib KarimMalika.

YK4279 directly inhibits EWSFLI1 Toretsky’s work on YK4279 led to the eventual development of TK216, a firstinclass small molecule that is now being studied by Oncternal Therapeutics in a clinical trial in patients with relapsed or refractory Ewing sarcoma. Furthermore, combinations of YK4279 with vincristine, paclitaxel or the Aurora kinase A inhibitor MLN37/Alisertib show strong synergy, particularly at low doses Thus, YK4279 could potentially be used as a singleagent or in combination therapies for the treatment of highrisk and relapsing neuroblastoma, as well as other cancers. We recently reported the development of YK4279, a small molecule inhibitor of EWSFLI1 oncoprotein in Ewing's Sarcoma Since ERG and ETV1 belong to the same class of ETS factors as FLI1, we tested the ability of YK4279 to inhibit biological functions of ERG and ETV1 proteins in prostate cancer.

YK 4279 is an inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWSFLI1 EWSFLI1 is a disordered protein that precludes standard structurebased smallmolecule inhibitor design EWSFLI1 binding to RNA helicase A.